Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Consolidative Thoracic Radiotherapy With Atezolizumab Maintenance in Extensive-Stage Small Cell Lung Cancer: The Phase 2 TREASURE Randomized Clinical Trial (AIO-TRK-0320).

JAMA oncology·2026
Same author

Correction: Circulating nitric oxide pathway metabolites in heart failure with preserved ejection fraction: a sex-stratified cross-sectional analysis.

Biology of sex differences·2026
Same author

Exercise-induced changes in hemostasis markers in marathon runners: effects of enzyme supplementation and determinants.

Frontiers in physiology·2026
Same author

Exercise in regional breast cancer with neoadjuvant anthracycline-based chemotherapy with immune checkpoint-inhibition: study protocol for a prospective randomised controlled trial.

Frontiers in oncology·2026
Same author

Circulating nitric oxide pathway metabolites in heart failure with preserved ejection fraction: a sex-stratified cross-sectional analysis.

Biology of sex differences·2026
Same author

Radiotherapy at the limits of age: evolving fractionation strategies, symptom palliation, and survival in nonagenarians.

Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology·2026

Related Experiment Video

Updated: May 15, 2026

Treatment of Liver Metastases Using an Internal Target Volume Method for Stereotactic Body Radiotherapy
08:54

Treatment of Liver Metastases Using an Internal Target Volume Method for Stereotactic Body Radiotherapy

Published on: May 8, 2018

Radiotherapy in marginal zone lymphoma.

Kristin Deinbeck1, Hans Geinitz, Bernhard Haller

  • 1Department of Radiation Oncology, Klinikum rechts der Isar, Technische Universität München, Munich, Germany.

Radiation Oncology (London, England)
|January 4, 2013
PubMed
Summary

Radiotherapy (RT) is effective for early-stage marginal zone lymphoma (MZL), showing excellent survival rates and no infield recurrences. Salvage RT also provides effective local control for relapsed MZL.

More Related Videos

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
04:04

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Published on: February 12, 2017

Related Experiment Videos

Last Updated: May 15, 2026

Treatment of Liver Metastases Using an Internal Target Volume Method for Stereotactic Body Radiotherapy
08:54

Treatment of Liver Metastases Using an Internal Target Volume Method for Stereotactic Body Radiotherapy

Published on: May 8, 2018

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
04:04

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Published on: February 12, 2017

Area of Science:

  • Oncology
  • Radiation Oncology

Background:

  • Marginal Zone Lymphoma (MZL) is a heterogeneous group of B-cell lymphomas.
  • Early-stage MZL can present with nodal or extranodal involvement.

Purpose of the Study:

  • To evaluate the efficacy of radiotherapy (RT) for early-stage nodal and extranodal marginal zone lymphoma (MZL).

Main Methods:

  • Retrospective review of 30 patients with stage I/II MZL treated with RT.
  • Tumor sites included orbit, stomach, head and neck, breast, and skin.
  • Median RT dose was 40 Gy.

Main Results:

  • Median follow-up was 103 months.
  • 5-year overall survival and event-free survival rates were 85% and 71%, respectively.
  • No infield recurrences observed; 6 patients had recurrence outside the radiation field, successfully treated with salvage RT.

Conclusions:

  • Localized extranodal MZL shows an excellent prognosis with moderate-dose RT.
  • RT is an effective salvage therapy for localized MZL recurrence.
  • Further studies are needed to determine optimal RT doses for MZL.